Neob

2 trials Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

2 Sponsors

7 Countries

Phase I/II

Phase I (FiH)

Phase I/II: 1 Phase I (FiH): 1

Oversight events:

2 unexpected events across 1 trial

View oversight register →

Indications tested

Breast cancer metastatic 1

Sponsors using this IMP

Advanced Accelerator Applications 1 Novartis Pharma AG 1

All trials

2 total

A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Phase I/II 6 countries Novartis Pharma AG
NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake. Ended

2023-507170-41-00 Phase I (FiH) 4 countries Advanced Accelerator Applications International S.A.

Showing 1–2 of 2 trials

← All drugs A–Z